scholarly journals Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study

2008 ◽  
Vol 3 (3) ◽  
pp. 258-264 ◽  
Author(s):  
Suresh Ramalingam ◽  
Judy Forster ◽  
Cynthia Naret ◽  
Terry Evans ◽  
Matt Sulecki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Monoclonal Antibody ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Igg1 Monoclonal Antibody ◽  
Epidermal Growth ◽  
Dual Inhibition

Tumor Epidermal Growth Factor Receptor Studies in Patients With Non-Small-Cell Lung Cancer or Head and Neck Cancer Treated With Monoclonal Antibody RG 83852

1994 ◽  
Vol 12 (7) ◽  
pp. 1526-1526 ◽  
Author(s):  
Roman Perez-Soler ◽  
Nicholas J. Donato ◽  
Dong M. Shin ◽  
Michael G. Rosenblum ◽  
Hua-Zhong Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Monoclonal Antibody ◽  
Epidermal Growth Factor Receptor ◽  
Head And Neck Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Epidermal Growth

The Acknowledgment regarding the report "Tumor Epidermal Growth Factor Receptor Studies in Patients With Non-Small-Cell Lung Cancer or Head and Neck Cancer Treated With Monoclonal Antibody RG 83852" (J Clin Oncol 12:730–739, 1994) should have read as follows: "We thank Dr Chris Tarr, Rhône-Poulenc/Rorer, and Dr Jon Holmlund, National Cancer Institute, for supplying RG 83852; Trupti Shah, Lora B. Thompson, Margaret Janus, Marc Lewis, and M. Perez for skillful technical assistance; and Kevin Flynn for editorial assistance."

Sign in / Sign up

Export Citation Format

Share Document